248 related articles for article (PubMed ID: 25749416)
1. Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults.
Gatell Artigas JM; Arribas López JR; Lázaro Y de Mercado P; Blasco Bravo AJ
Enferm Infecc Microbiol Clin; 2016; 34(7):427-30. PubMed ID: 25749416
[TBL] [Abstract][Full Text] [Related]
2. Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults.
Gatell JM; Arribas JR; Lázaro P; Blasco A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19603. PubMed ID: 25394107
[TBL] [Abstract][Full Text] [Related]
3. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Berenguer J; Rivero A; Blasco AJ; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; Lázaro P; López JC; Llibre JM; Lozano F; Miró JM; Podzamczer D; Tuset M; Gatell JM;
Enferm Infecc Microbiol Clin; 2016; 34(6):361-71. PubMed ID: 26321131
[TBL] [Abstract][Full Text] [Related]
4. Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Rivero A; Pérez-Molina JA; Blasco AJ; Arribas JR; Crespo M; Domingo P; Estrada V; Iribarren JA; Knobel H; Lázaro P; López-Aldeguer J; Lozano F; Moreno S; Palacios R; Pineda JA; Pulido F; Rubio R; de la Torre J; Tuset M; Gatell JM
Enferm Infecc Microbiol Clin; 2017 Feb; 35(2):88-99. PubMed ID: 27459919
[TBL] [Abstract][Full Text] [Related]
5. Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Blasco AJ; Llibre JM; Berenguer J; González-García J; Knobel H; Lozano F; Podzamczer D; Pulido F; Rivero A; Tuset M; Lázaro P; Gatell JM;
Enferm Infecc Microbiol Clin; 2015 Mar; 33(3):156-65. PubMed ID: 25175171
[TBL] [Abstract][Full Text] [Related]
6. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial.
Cahn P; Andrade-Villanueva J; Arribas JR; Gatell JM; Lama JR; Norton M; Patterson P; Sierra Madero J; Sued O; Figueroa MI; Rolon MJ;
Lancet Infect Dis; 2014 Jul; 14(7):572-80. PubMed ID: 24783988
[TBL] [Abstract][Full Text] [Related]
7. [Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
Blasco AJ; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Llibre JM; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):283-93. PubMed ID: 22525829
[TBL] [Abstract][Full Text] [Related]
8. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013].
Blasco AJ; Llibre JM; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
Enferm Infecc Microbiol Clin; 2013 Nov; 31(9):568-78. PubMed ID: 23969276
[TBL] [Abstract][Full Text] [Related]
10. [Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain].
Smets E; Brogan AJ; Hill A; Adriaenssen I; Sawyer AW; Domingo-Pedrol P; Gostkorzewicz J; Ledesma F
Enferm Infecc Microbiol Clin; 2013; 31(7):430-6. PubMed ID: 23260386
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults.
Pérez-Molina JA; Martínez E; Blasco AJ; Arribas JR; Domingo P; Iribarren JA; Knobel H; Lázaro P; López-Aldeguer J; Lozano F; Mariño A; Miró JM; Moreno S; Negredo E; Pulido F; Rubio R; Santos J; de la Torre J; Tuset M; von Wichmann MA; Gatell JM
Enferm Infecc Microbiol Clin (Engl Ed); 2019 Mar; 37(3):151-159. PubMed ID: 29884455
[TBL] [Abstract][Full Text] [Related]
12. Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
Rivero A; Pérez-Molina JA; Blasco AJ; Arribas JR; Asensi V; Crespo M; Domingo P; Iribarren JA; Lázaro P; López-Aldeguer J; Lozano F; Martínez E; Moreno S; Palacios R; Pineda JA; Pulido F; Rubio R; Santos J; de la Torre J; Tuset M; Gatell JM
Enferm Infecc Microbiol Clin (Engl Ed); 2018 May; 36(5):268-276. PubMed ID: 28532596
[TBL] [Abstract][Full Text] [Related]
13. [Positioning of lopinavir/ritonavir in antiretroviral treatment schemes].
Camacho Á; Rivero A
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():31-4. PubMed ID: 25542874
[TBL] [Abstract][Full Text] [Related]
14. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
15. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ
Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210
[TBL] [Abstract][Full Text] [Related]
16. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
17. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
Arribas JR; Girard PM; Landman R; Pich J; Mallolas J; Martínez-Rebollar M; Zamora FX; Estrada V; Crespo M; Podzamczer D; Portilla J; Dronda F; Iribarren JA; Domingo P; Pulido F; Montero M; Knobel H; Cabié A; Weiss L; Gatell JM;
Lancet Infect Dis; 2015 Jul; 15(7):785-92. PubMed ID: 26062880
[TBL] [Abstract][Full Text] [Related]
18. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Bunupuradah T; Chetchotisakd P; Ananworanich J; Munsakul W; Jirajariyavej S; Kantipong P; Prasithsirikul W; Sungkanuparph S; Bowonwatanuwong C; Klinbuayaem V; Kerr SJ; Sophonphan J; Bhakeecheep S; Hirschel B; Ruxrungtham K;
Antivir Ther; 2012; 17(7):1351-61. PubMed ID: 23075703
[TBL] [Abstract][Full Text] [Related]
19. Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Rough K; Seage GR; Williams PL; Hernandez-Diaz S; Huo Y; Chadwick EG; Currier JS; Hoffman RM; Barr E; Shapiro DE; Patel K;
N Engl J Med; 2018 Apr; 378(17):1593-1603. PubMed ID: 29694825
[TBL] [Abstract][Full Text] [Related]
20. [Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy].
Blasco AJ; Arribas JR; Clotet B; Domingo P; González-García J; López-Bernaldo JC; Llibre JM; Lozano F; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM
Enferm Infecc Microbiol Clin; 2011 Dec; 29(10):721-30. PubMed ID: 22014894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]